Month: January 2024

VALENCIA, Calif., Jan. 10, 2024 (GLOBE NEWSWIRE) — AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “Company”), a commercial-stage regenerative medicine company focused on first-in-class devices and autologous cellular therapies for skin restoration, today announced it has entered into an exclusive multi-year distribution agreement with Stedical Scientific, Inc. to commercialize PermeaDerm® Biosynthetic Wound Matrix in the United States. PermeaDerm is cleared by the Food and Drug Administration as a transparent matrix for use in the treatment of a variety of wound types until healing is achieved. Under the terms of the agreement, AVITA Medical will hold the exclusive rights to market, sell, and distribute PermeaDerm products, including any future enhancements or modifications, within the United States. The initial term is for...

LIVERMORE, Calif., Jan. 10, 2024 (GLOBE NEWSWIRE) — FormFactor, Inc. (Nasdaq: FORM) will report financial results for its 2023 fiscal fourth quarter on Wednesday, February 7th, 2024, at 1:25 p.m. Pacific Time. The public is invited to listen to a live webcast of FormFactor’s conference call on the Investors section of the company’s web site at www.formfactor.com. To Listen via Telephone: Preregistration is required.  Please preregister by clicking here. Upon registering, you will be emailed a dial-in number, direct passcode and unique PIN. A replay of the conference call will be available approximately two hours after the conclusion of the call. The replay will be available on the Investors section of our website www.formfactor.com. About FormFactor:FormFactor, Inc. (NASDAQ: FORM), is a leading provider of essential...

Strategic Investment Accelerates Reborn Coffee’s International Presence, Signaling Strong Confidence in Global Market Expansion BREA, Calif., Jan. 10, 2024 (GLOBE NEWSWIRE) — Reborn Coffee, Inc. (NASDAQ: REBN) (“Reborn”, or the “Company”), a California-based retailer of specialty coffee, today announced a substantial investment commitment from its Chairman, Farooq Arjomand, demonstrating his confidence in the company’s direction and potential. This move represents a significant endorsement of the company’s current valuation and growth prospects, coming at a strategic time following the opening of Reborn’s flagship store in Malaysia. This new venture opens a window of growth and opportunities in Southeast Asia and precedes the company’s planned expansion into other vibrant markets, including...

Inventiva intends to use the proceeds to fund part of its ongoing pivotal NATiV3 Phase III clinical trial evaluating lanifibranor in patients with NASH. This second tranche carries an interest rate of 7% annually and has a maturity of 3 years and a repayment in fine which is expected to occur after the anticipated publication of the results of the NATiV3 Phase III trial evaluating lanifibranor in patients with NASH, expected in the first half of 2026. The €25 million supports Inventiva’s estimated cash runway1 until the beginning of the third quarter of 2024.Daix (France), Long Island City (New York, United States), January 10, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with non-alcoholic...

GLENVILLE, N.Y., Jan. 10, 2024 (GLOBE NEWSWIRE) — TrustCo Bank Corp NY (TrustCo, Nasdaq: TRST) today announced that it will release fourth quarter 2023 results after the market close on January 22, 2024. Results are released on the 21st of the reporting months (January, April, July and October), or on the next day that equity markets are open if the 21st falls on a Friday, weekend or holiday. A conference call to discuss the results will be held at 9:00 a.m. Eastern Time on January 23, 2024. Those wishing to participate in the call may dial toll-free for the United States at 1-833-470-1428, and for Canada at 1-833-950-0062, Access code 813290.   A replay of the call will be available for thirty days by dialing toll-free for the United States at 1-866-813-9403, Access code 303906. The call will also be audio webcast at https://events.q4inc.com/attendee/827223195,...

Oakbridge Crossing by Toll BrothersOakbridge Crossing, a new luxury home community by Toll Brothers, is coming soon to the Dallas-Fort Worth area.Oakbridge Crossing by Toll Brothers“Residents of the Oakbridge Crossing community will enjoy the best of luxury living in a prime location with excellent Flower Mound schools and within walking distance to outstanding restaurants and entertainment,” said Jay Saunders, Division President of Toll Brothers in Dallas-Fort Worth.FLOWER MOUND, Texas, Jan. 10, 2024 (GLOBE NEWSWIRE) — Toll Brothers, Inc. (NYSE:TOL), the nation’s leading builder of luxury homes, today announced its newest community, Oakbridge Crossing, is coming soon to Flower Mound, Texas. Land development is underway, the Sales Center will open in early summer of 2024, and the future model home will debut in...

Beverly Hills, California., Jan. 10, 2024 (GLOBE NEWSWIRE) — Nordicus Partners Corporation (OTC PINK: NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in providing Nordic and U.S. Life Sciences companies with optimal conditions to establish themselves on the U.S. market, today announced it entered into a paying Consultancy Agreement with Orocidin A/S in Denmark. Orocidin A/S (“Orocidin”) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the preferred treatment against aggressive periodontitis. Henrik Rouf, CEO of Nordicus, said, “We are pleased that Orodicin chose Nordicus as their exclusive consulting partners to assist with getting established on the U.S. marketplace and becoming Nordicus’ first revenue generating customer. As...